

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

4865-79

APPLICANT

GIANNINI ET AL.

FILING DATE

August 10, 2006

SERIAL NO.

10/564,637

GROUP

1625

(Use several sheets if necessary)


U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Li et al, "Three Inhibitors of Type 1 Human Immunodeficiency Virus Long Terminal ...", Proc. Natl. Acad. Sci. USA, Vol. 99, pp. 1839-1842, March, 1993.
	Garcia-Carbonero et al, "Current Perspectives on the Clinical Experience, Pharmacology ...", Clinical Cancer Research, Vol. 8, 641-661, March 2002.
	Dallavalle et al, "Perspectives in Camptothecin Development", Expert Opinion Ther. Patents (2002) 12(6) 837; XP-002251117.
	Lesueur-Ginot et al, "Homocamptothecin, an E-Ring Modified Camptothecin ...", Cancer Research 59, 2939-2943, June 15, 1999.
	Vladu et al, "7- and 10-Substituted Camptothecins: Dependence of Topoisomerase ...", Molecular Pharmacology, 57:243-251 (2000).
	Dallavalle et al, "Novel 7-Oxyiminomethyl Derivatives ...", J. Med. Chem. 2001, 44, 3264-3274.
	Kantarjian et al, "Phase I Study of Topotecan, A New Topoisomerase ...", Blood, Vol. 81, No. 5 (March 1), 1993, pp. 1146-1151.
	Kaufmann et al, "Topoisomerase II Levels and Drug Sensitivity ...", Blood, Vol. 83, No. 2 (January 15), 1994; pp. 517-530.
	Lichtman et al, "Chemotherapy in the Elderly ...", Cancer Control, November/December 2000, Vol. 7, No. 6., pages 548-556.
	Bodley et al, "Molecular and Cytotoxic Effects ...", Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 3726-3730, April 1995.
	Priel et al, "The Topoisomerase I Inhibitor ...", Journal of Virology, August 1991, p. 4137-4141.
	Lavergne et al, "Homocamptothecins: Synthesis and Antitumor Activity ...", J. Med. Chem. 1998, 41, 5410-5419.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial this form with next communication to application.